Biocytogen is a global biotechnology company listed on the Hong Kong Stock Exchange (HKEX: 1110.HK) dedicated to discovering, developing, and delivering innovative antibody-based therapeutics. The company leverages its proprietary RenMice® platforms for fully human monoclonal and bispecific antibody discovery, alongside extensive capabilities in gene editing and preclinical animal model development. Biocytogen's integrated approach supports the entire drug discovery pipeline, from target validation to clinical candidate selection, through in-house projects and extensive global partnerships. Their mission is to become a global leader in new drug research and development for the benefit of patients worldwide.
Serves as the main operational and R&D center, overseeing global strategy, core research programs including antibody discovery and gene editing, preclinical studies, and corporate administrative functions.
Features state-of-the-art research laboratories, advanced animal model facilities including large-scale specific pathogen-free (SPF) animal housing, and collaborative workspaces designed to foster cutting-edge scientific discovery.
A research-driven and innovative environment characterized by scientific rigor, collaboration among multidisciplinary teams, and a strong commitment to accelerating the development of new medicines.
Strategically positioned in a major Chinese biotech cluster, providing access to a rich talent pool, academic collaborations, and proximity to the rapidly expanding Asian pharmaceutical market. It underpins Biocytogen's R&D capabilities and global ambitions.
Biocytogen operates globally with key facilities and offices in China (Beijing, Haimen), the United States (Woburn, MA; Foster City, CA), and Germany (Heidelberg). This international network supports worldwide R&D collaborations, antibody discovery projects, preclinical services, clinical trial management, and business development activities, enabling the company to serve pharmaceutical and biotech partners across Asia, North America, and Europe.
No.12A Life Science Park Road, Changping District
Beijing
Beijing
China
Address: 400 TradeCenter Dr., Suite 1680, Woburn, MA 01801, USA
To strengthen Biocytogen's presence in the key US East Coast biotech hub, fostering collaborations and providing localized support for its antibody discovery platforms and preclinical services.
Address: Building B16, Biomedical Park, Linjiang New District, Haimen, Jiangsu, 226100, P.R.China
Enhances Biocytogen's capacity for large-scale production of animal models and antibodies, and supports extensive preclinical research services, leveraging regional biomanufacturing and research strengths.
Address: Biocytogen GmbH, Technology Park Heidelberg, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany
To establish and grow Biocytogen's footprint in the European biotechnology landscape, driving partnerships and providing tailored services to European clients.
Address: 950 Tower Lane, Suite 1030, Foster City, CA 94404, USA
To effectively manage and execute clinical trials, particularly in the US, leveraging the proximity to the West Coast biotech cluster and its associated clinical research infrastructure and expertise.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biocytogen' leadership includes:
Biocytogen has been backed by several prominent investors over the years, including:
In early 2023, Biocytogen experienced a significant transition in its financial leadership with the appointment of a new Chief Financial Officer. The broader executive team has largely maintained stability since this change, focusing on strategic growth and pipeline advancement.
Discover the tools Biocytogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biocytogen typically uses a standard professional email format for its employees, most commonly [firstname].[lastname]@biocytogen.com. Variations may exist for general inquiries or specific regional business development contacts (e.g., bd_us@biocytogen.com).
[first].[last]@biocytogen.com
Format
john.smith@biocytogen.com
Example
85%
Success rate
Biocytogen News Room • May 14, 2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced an antibody evaluation and option agreement with Ono Pharmaceutical Co., Ltd. for a jointly selected antibody target. Biocytogen will grant Ono an option to license antibodies generated by Biocytogen for the development, manufacturing and commercialization of antibody drug conjugates (ADCs) and other GPRC5D-targeting drugs globally....more
Biocytogen News Room • April 29, 2024
Biocytogen's subsidiary, Eucure Biopharma, has entered into a clinical trial collaboration and supply agreement with Merck (MSD) to evaluate YH008, a PD-1/IL-2 bispecific antibody, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors in Australia....more
Biocytogen News Room • April 2, 2024
Biocytogen announced an antibody evaluation and option agreement with Takeda. Under the agreement, Takeda will evaluate certain Biocytogen-proprietary monoclonal antibodies with the potential for therapeutic drug development. Takeda will have the option to license selected antibodies for global development and commercialization....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biocytogen, are just a search away.